ESTRO 37: Vendor launches, updates and highlights in Barcelona

By News Release


At ESTRO 37, Elekta focuses on millimeter precision, personalized cancer care

At the European Society for Radiotherapy and Oncology (ESTRO) 37th Annual Conference, April 20-24 in Barcelona, Elekta will demonstrate how advances in both radiation and medical oncology are paving the way to deliver more efficient, personalized cancer care and improved patient outcomes.

“Breakthroughs in clinical and scientific cancer research are increasing what we know about cancer. Consequently, Elekta is delivering new precision treatment modalities and digital solutions so that clinicians can better plan, treat and monitor outcomes for each individual patient – and population,” said Dr. Richard Hausmann, Elekta’s President and CEO. “Innovation has, is and always will be part of Elekta’s DNA, as evidenced by two key initiatives: the Elekta MR-linac system, soon to be the first magnetic resonance/radiation therapy (MR/RT) system in the world offering simultaneous high-field imaging and treatment without compromise; and our collaboration with IBM Watson Health to bring artificial intelligence (AI) and machine learning to the field of oncology. At ESTRO 37, we are also celebrating the 50th anniversary of Gamma Knife surgery, demonstrating our commitment to continual advancement and sustainable innovation.”

Visitors to Elekta’s booth 300 will have the opportunity to participate in interactive demonstrations and learn more about recent Elekta breakthrough technologies, including:

  • The power of MR/RT with Elekta MR-linac, the only system that integrates an advanced linear accelerator with cutting-edge, high-field (1.5 Tesla) magnetic resonance imaging without compromising either system. It is the first system to achieve the technological feat of simultaneous radiation delivery and fast acquisition of high-quality, high-field MR images, providing the ability to “see what you treat” and respond based on what is being seen. Elekta MR-linac has extraordinary potential for ushering in a new paradigm of cancer care.
  •  MOSAIQ ​with Watson for Oncology – Elekta is collaborating with IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care solutions. This collaboration unites pioneers in cancer care and AI to transform big data into personalized and precision cancer therapies management. With intelligent automation and actionable analytics, MOSAIQ enables value-based practice optimization and supports clinical decisions that can help outsmart cancer.
  • Leksell Gamma Knife Icon is the clear choice for intracranial precision radiosurgery with unrivaled accuracy and superior dose distribution – backed by extensive, and growing, published data. Elekta’s Icon precisely delivers planned doses efficiently and simply, affording better protection to healthy brain tissue compared with other radiation therapy systems. Gamma Knife clinics around the world have often reported higher productivity, cost efficiency and reliable performance over the lifetime of the system.
  • Versa HD is a highly versatile, all-in-one radiotherapy system that overcomes stereotactic complexity with high definition dynamic radiosurgery (HDRS). Versa HD optimizes accuracy with anatomically-focused guidance solutions, delivering the flexibility to treat more patients and a wider variety of indications in standard treatment slots regardless of anatomy, indication or complexity. Integrated with Brainlab ExacTrac, Versa HD offers the highest end-to-end clinical accuracy with Monaco treatment planning and iView Dose – pushing the boundaries of your stereotactic capabilities.
  • Elekta’s brachytherapy solutions are an indispensable part of radiation therapy that can boost survival rates, reduce toxicity and improve the quality of life with fewer side effects compared to surgery. Venezia, the newest Advanced Gynecological Applicator, allows clinicians to treat advanced stage cervical tumors that previously required specialized techniques such as free-hand needle placement. 

Elekta is also hosting educational meetings and symposia throughout the conference, including:

  • An Elekta Lunch Symposium on “Driving the Transformation of Cancer Care” will be held April 21 from 1:15 p.m. to 2:15 p.m. Key topics covered at the symposium include:
    • Elekta MR/RT: Moving Toward Clinical Introduction of Transformative Cancer Care. Presented by Prof. Robert Huddart, MD, Institute of Cancer Research/Royal Marsden NHS Foundation Trust (UK) 
    • The Advent of AI in Radiation Therapy: MOSAIQ & Watson for Oncology by Susan McLaughlin, Global GTM Client Engagement 
  • An evening event at the Museu Nacional d’Art de Catalunya in Barcelona with the theme of "Future in Cancer Care" will include presentations on how innovation is transforming cancer care and deep learning in RT and adaptive radiotherapy, alongside networking opportunities.

To learn more about these events, visit: For live updates from ESTRO 37, follow @Elekta on Twitter. 

Elekta MR-linac is a work in progress and not available for sale or distribution.


ESTRO 37: IBA showcases positioning a healthcare center at forefront of cancer care

BA (Ion Beam Applications) will demonstrate how to secure the performance, the investment and the future of establishing a proton therapy center at the 37th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting and Exhibition being held in Barcelona April 20-24.
Proton therapy is considered one of the most advanced forms of radiation therapy. When investing in a technology that will last for over 30 years, the selection of the right partner is a crucial step in the buying process. During the ESTRO meeting, proton therapy practitioners will share their experience about securing, installing and operating a proton therapy center with IBA during open sessions on the IBA booth as well as at the IBA Symposium. Aiming to offer seamlessly integrated proton therapy solutions, IBA will showcase the latest advances in its partnerships with the best leaders in radiation oncology at its booth, #1400. 

Latest news from proton therapy practitioners
Securing the performance in proton therapy
After a fast installation of the ProteusPLUS* solution by IBA, the University Medical Center Groningen (UMCG) Proton Therapy Center successfully treated the  first patient in The Netherlands in January 2018 and announced the acceptance of the center’s second proton therapy room. Benefiting from a series of some of the world’s most advanced technology in proton therapy, the number of patients being treated at the center is ramping up quickly and will continue to rise with the additional treatment capacity.

Stefan Both, Professor & Head of Medical Physics at UMCG, will share his experience of UMCG’s path towards a SMART Proton Pencil Beam Scanning Clinic on the IBA booth, #1400 on Saturday, April 21st, from 10:00 AM to 10:30 AM.

Securing the investment in proton therapy
On April 11th, following a record nine-month installation program by IBA, Proton Partners International announced it has treated the first patient in the UK with high energy proton beam therapy. The first patient was treated on the ProteusONE* solution at Rutherford Cancer Centre in Newport, South Wales. The patients benefit from the latest Intensity Modulated Proton Therapy (IMPT) to adjust the depth and intensity of the beam to the shape of the tumor. Proteus®ONE solution includes Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities making ProteusONE the only compact solution ready for adaptive treatment. Proton Partners International plans to build eight centers in the UK to provide a treatment center within 90 minutes of any patient’s home.

John Pettingell, Chief Physicist & Head of Radiotherapy at the Rutherford Cancer Centres, will describe his experience in delivering the UKs first high energy proton therapy service on Saturday, April 21st, from 3:45 PM to 4:15 PM at IBA’s booth, #1400.

Securing the future in proton therapy
OncoRay – National Center for Radiation Research in Oncology, Dresden, Germany, is a leading research center with very advanced research in particle physics and radiation therapy. OncoRay is jointly operated by the Faculty of Medicine and the University Hospital Carl Gustav Carus at the Technical University Dresden and the Helmholtz-Zentrum Dresden-Rossendorf, Dresden. As part of the joint R&D program with IBA, OncoRay is currently working on the development of an MR-integrated proton therapy solution. 

Aswin Hoffmann, Head of MR-Therapy Research at OncoRay will share the latest advances on this project related to a proof of concept with the first in-beam MRI on Sunday, April 22nd, from 3:45 PM to 4:15 PM at IBA’s booth, #1400.

Partnering with key market leaders in radiation oncology for optimal healthcare solutions

Following its open integration approach, IBA will showcase multiple workflow solutions to integrate proton therapy in the clinic.

IBA offers perfect integration with Elekta’s MOSAIQ oncology information system that will be demonstrated at IBA’s booth. IBA and Elekta have signed a memorandum of understanding in order to develop, among others, new functionalities for proton therapy treatment in Elekta’s Monaco® treatment planning system and MOSAIQ® oncology information system and provide clinical pathway-driven adaptive particle therapy. The purpose is to offer a seamless experience across modalities for comprehensive radiotherapy departments and further improve patient care.

IBA is in a long-term strategic collaboration with Philips. By combining their respective expertise in image guidance and therapy, Philips and IBA continue to co-innovate in diagnostic and therapeutic oncology solutions with the ultimate objective of enabling more effective and personalized cancer care. Proton Partners International chose to partner with IBA and Philips in an ambitious plan to build a network of state-of-the-art proton therapy centers in the UK, and in the Middle East. All centers will integrate IBA’s latest Image Guided IMPT combined with Philips’ Pinnacle3 Treatment Planning System, as well as Philips’ Big Bore CT, and Philips’ Ambient Experience, a patient-focused healthcare environment designed to create a more comfortable and soothing experience for patients and staff. 

IBA is partnering with RaySearch Laboratories AB (publ) to advance adaptive proton therapy in combining respective technologies. In both RayStation and RayCare**, as well as in the IBA delivery solutions, combined features dedicated software interfaces allow for seamless workflow integration with optimized performance. A real-time demonstration will be displayed at IBA’s booth. 

IBA Proton Therapy Conference

On Saturday, April 21st, 2018, IBA is hosting a symposium in Barcelona with presentations from experienced speakers in proton therapy:

  • Professor Debus, from Heidelberg University Hospital, will explain the benefits of proton therapy for key clinical indications;
  • The model based approach for patient selection will be presented by Professor Langendijk from the University Medical Center in Groningen;
  • Professor Depuydt, from ParTICLe Proton Therapy UZ Leuven, will describe the integration of proton therapy in an existing oncology center. 

Registration to the IBA proton therapy event is available here.

Sun Nuclear launches SunCHECK 2.0, on display at ESTRO 37

Sun Nuclear Corporation has released significant new functionality for its SunCHECK Platform – an integrated, independent solution for Patient and Machine QA in radiation therapy. Designed to support a broad range of planning and delivery technologies, SunCHECK 2.0 streamlines and standardizes workflows – allowing greater overall focus on Patient Safety.

With SunCHECK, hospitals and cancer centers gain: 

  • One Solution for Radiation Therapy QA. Managing all Patient and Machine QA in a consistent way helps reduce the likelihood of errors going undetected.
  • Speed and Efficiency through Automation. Less time spent on manual tasks means more bandwidth for data analysis, clinical decisions and continuous improvement.
  • Access from Anywhere. SunCHECK is browser-based and accessible to staff through a secure network. From dashboard reviews to deep data analysis, a single database drives the entire process.

Within the SunCHECK Platform, SunCHECK Patient integrates all phases of patient QA into a seamless workflow, including Secondary Checks, Phantomless Pre-Treatment QA and In-Vivo Monitoring.

Key new functionality includes: 

  • EPID-based Transit Dosimetry, compliant with 2013/59/EURATOM, Article 83
  • Pre-set, yet customizable, dose tolerances per phase, with Universal Metrics
  • Expanded 3D secondary dose and MU calculation support, including for TomoTherapy (Monte Carlo-based), HDR Brachytherapy and stereotactic cone systems

SunCHECK Machine helps to improve standardization and ease compliance reporting for Daily, Monthly and Annual QA – across locations, machines and staff.

Key new functionality includes: 

  • Standard and complete TG-142 templates
  • User-friendly editing or creation of customized QA templates and tasks
  • Direct device connectivity to Sun Nuclear’s Daily QA 3 and IC PROFILER solutions
  • Centralized data storage and flexible reporting for accreditation and compliance

“We are excited to release SunCHECK 2.0, and to make flexible workflow automation a reality in radiation therapy QA,” said Jeff Simon, CEO of Sun Nuclear. “As a global partner to both radiation oncology clinics and technology vendors, we know independence and integration are equally important requirements. SunCHECK 2.0 balances these requirements to improve Patient Safety.”

SunCHECK 2.0 will feature prominently in the Sun Nuclear booth (#2300) at the ESTRO 37 congress, 20-24 April, in Barcelona, Spain. Limited space is available for related educational talks and demonstrations.

Varian showcasing advanced cancer care solutions at ESTRO 37

Varian has announced it will be showcasing the expanded imaging and treatment capabilities of the Halcyon system and the new version of the Velocity cancer imaging software, April 20-23 in Barcelona, Spain at ESTRO 37 (European Society for Radiotherapy & Oncology) meeting, booth 2800. Halcyon 2.0 features kV Cone-beam CT imaging to provide better soft tissue definition. Velocity 4.0 includes Rapidsphere, a module for Y90 Selective Internal Radiation Therapy (SIRT) dosimetry analysis.

Additional Varian solutions being demonstrated at ESTRO 37 includes:

  • HyperArc – Designed to automate and simplify sophisticated advanced treatments such as stereotactic radiosurgery (SRS) and make them available to more cancer patients around the world
  • RapidPlan with multicriteria optimization (MCO) - RapidPlan is designed to simplify and accelerate the planning process for sophisticated cancer treatments like SRS, stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and RapidArc radiotherapy. MCO allows clinicians to explore what happens when different clinical criteria are varied, such as the degree to which particular organs are spared versus coverage of the targeted tumor.
  • Mobius – Recently acquired by Varian, Mobius software solutions provide for patient treatment plan and machine QA
  • TrueBeam v2.7 with Iterative CBCT– On the TrueBeam platform, Iterative CBCT produces exceptionally high-quality images for better visualization of soft tissue structures
  • ProBeam proton therapy, configurable as single- or multi-room solutions featuring gantries that rotate a full 360 degrees, RapidScan high-speed pencil-beam scanning for single-breath-hold lung SBRT and Iterative CBCT for enhanced soft tissue resolution enhancing your ability to treat complex cases more effectively and efficiently.
  • Brachytherapy: Varian's integrated brachytherapy solution includes VariSeed LDR treatment planning system, Vitesse real-time planning for HDR brachytherapy and BrachyVision 3D treatment planning system 

Halcyon 2.0 is currently Works in Progress and not available for sale.

In the EU, the ProBeam RapidScan and Iterative CBCT feature, Velocity 4.0 and Mobius software solutions are Works in Progress and currently unavailable for sale.

Varian is hosting an international oncology summit for customers to kick off its ESTRO activities on April 20th at the Palau Congressos Barcelona.

When: ESTRO 37 is April 20-23, 2018. The exhibition is open from 9:30am – 5pm daily.

Where: Booth # 2800, CCIB, Rambla Prim 1-17, Barcelona, Spain


AT ESTRO 37, Philips focuses on enhancing precision, managing radiation, and reducing time to treatment

With its dedicated radiation oncology solutions that help deliver more precise, comprehensive treatment plans, Philips at ESTRO 37 is focused on enhancing precision, managing radiation successfully and reducing time to treatment. The company is highlighting:

  1. A collaboration with Sun Nuclearto integrate its suite of PlanIQ softwarewith Philips’ Pinnacle3 16.2 Auto-Planning to aid clinicians in establishing feasible treatment goals.
  2. The company’s portfolio of solutions, including integrated systems and software, to help enable a confident path to treatment focused on the key areas of imaging and simulation, treatment planning, and tumor follow-up and response. These include iPatient for Big Bore CT, IQon Spectral CT Elite, the Philips Ingenia MR-RT platform, the MR simulation package for Elekta MR-linac, Vereos Digital PET/CT, Pinnacle316.2 with Auto-Planning and IntelliSpace Portal 10.

Additionally, Philips technology was used to treat the first patient in the UK with high-energy proton beam therapy at Proton Partners’ new Rutherford Cancer Centre in Newport, South Wales. It’s the first oncology clinic in the UK to provide high-energy proton beam therapy for targeted tumor treatments. To plan patient treatment, the solution integrates Philips’ Big Bore CT and Pinnacle3 Treatment Planning System. More info can be found here.


RayCare’s Machine Learning and latest innovations on display at ESTRO 37

RaySearch will be exhibiting at the ESTRO 37 congress April 20-24 in Barcelona, Spain. In addition to the latest advances in machine learning technology* and online adaptive therapy, RaySearch will demonstrate innovations in the RayCare* oncology information system, now released. RaySearch will also show the new features in the latest release of its treatment planning system, RayStation. Attendees are welcome to visit RaySearch at booth #1000, and demonstrations can be booked at:

New Features in RayStation 7*
New functionality and a wide range of general improvements will be on show. The latest RayStation release that will be demonstrated contains several enhancements to existing functionality that will contribute to improved workflows and planning efficiency, including integration with RayCare, the next-generation oncology information system. Major new functionality includes the addition of robust constraints in multi-criteria optimization (MCO), simulated organ motion for robust optimization and evaluation, multi-atlas-based segmentation and conformal arc planning for photons. 

Significant additions on the proton side include support for Hyperscan pencil beam scanning technology from Mevion Medical Systems, and support for uniform scanning for proton therapy systems from Mitsubishi Electric. Other proton therapy improvements include snout rotation for passive proton techniques and MLC collimation for PBS and passive techniques. 

RayCare: The Next-Generation Oncology Information System
RayCare 1 was launched in December 2017 and is already in clinical use at Iridium Cancer Network in Belgium. Iridium will present its first experiences with the system during the RaySearch lunch symposium on April 21.

Development of upcoming versions of RayCare is going forward rapidly. RaySearch will demonstrate the latest improvements and features, including advanced workflow management tools and integrated planning workflow support for RayStation. RayCare active workflows are highly configurable and the task management features enable an integrated planning experience with RayStation, supporting automation of process steps and communication around planning tasks.

Other features on show include the built-in PACS system, which supports automation of imaging workflows, and the control room client for radiation therapy treatment management.

Machine Learning Demonstrations
The Machine Learning department at RaySearch is developing solutions for automating workflows and supporting the user in RayStation and RayCare. At ESTRO 37, RaySearch will demonstrate two RayStation applications of machine learning: automated treatment planning and automated organ segmentation. The automated planning application uses machine learning algorithms to generate a set of treatment plans in minutes, based on clinical treatment data from Princess Margaret Cancer Centre and University Medical Centre Groningen. Automated organ segmentation uses deep neural networks to generate a set of 3D organ volumes within seconds.

RaySearch will also present the machine learning and analytics framework concept that will enable RayStation and RayCare to become learning systems.

Lunch symposium: Advancing Cancer Treatment Through Software Innovation
On April 21, 13:15 - 14:15, floor P1, room 11, RaySearch will hold a lunch symposium focused on how software is driving innovation in oncology.
Moderator: Rik Westendorp, Medical Physicist, Radiotherapiegroep, Deventer, Holland

Fight cancer with code
Johan Löf, Founder & CEO, RaySearch Laboratories (publ), Stockholm, Sweden

First clinical experience with RayCare 1 in a multi-institutional setting
Carole Mercier, Radiation Oncologist, Iridium Cancer Network, Belgium

Efficiency improvements with RayStation
Nick West, Lead Clinical Scientist, The Northern Centre for Cancer Care, Newcastle, UK

Questions and conclusion session
Rik Westendorp, Medical Physicist, Radiotherapiegroep, Deventer, Holland


Accuray showcasing patient-first cancer treatments at ESTRO 37

Accuray Incorporated will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The April 20-24 meeting will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's CyberKnife and Radixact Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.

"This year, Accuray has chosen a theme which is anchored in our company culture and conveys our new corporate positioning: 'Innovating Patient-First Cancer Treatment.' This is not just a tagline. It is who we are, what we do and what makes us different. As the fight against cancer grows more complex, we will continually introduce new thinking and fresh tools to drive patient outcomes to entirely new levels," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray.

Special Events: Accuray Booth #1700

As described in a company release, Accuray is building on its history of innovation with a new approach for demonstrating product features and benefits, and a new award recognizing customer advances achieved with its products.

April 21, 2018 at 9:30 a.m.: Unveiling of hologram technology, "viRTual - Where Art Meets Science"

April 21, 2018 at 2:10 p.m.: Announcement of first annual ESTRO Accuray Innovation Awards

Accuray ESTRO37 Highlights: Advances in Software Solutions

  • VOLO™ Technology for the CyberKnife System: a state-of-the art optimizer that simplifies the process of creating treatment plans, improves plan quality and enables more efficient exploration of the tradeoffs between treatment time and plan quality. Preliminary data indicates that the VOLO technology will provide a significant reduction in optimization time, as well as a reduction in overall treatment time. Technology under development for the CyberKnife System – not available for sale.
  • CTrue™ IR (Iterative Reconstruction) for the Radixact System: this new image guidance software improves soft-tissue contrast and reduces noise, enhancing image quality, while maintaining the same low imaging dose and fast reconstruction time as earlier versions of the software. Patient workflows are also more efficient, facilitating the delivery of precise treatments more quickly, for more patients. 

Radiation Oncology Experts Share First-Hand Experience with Accuray Technologies

ESTRO attendees are invited to take part in multiple educational opportunities. Over the course of the meeting, a symposium and numerous Accuray Exchange in Radiation Oncology (AERO™) sessions will provide information on a range of subjects designed to advance clinical practice and enhance patient outcomes.

Click here for more information about the daily sessions and here for details on the symposium.

  • Accuray Symposium: Saturday, April 21 from 13:15 pm to 14:15 pm in Room 116
    • Prof. Veronica Dell'Acqua, European Institute of Oncology (IEO), Milan(Italy) will discuss how to improve the quality of breast cancer treatments with the TomoTherapy® System
    • Dr. Maaike Milder, Erasmus MC, Rotterdam (Netherlands) will share her experience using the CyberKnife® platform to minimize margins and maximize precision and accuracy
  • AERO Sessions: April 21st – April 23rd
    Interactive sessions will be held daily throughout the meeting at the Accuray booth. Attendees will have the opportunity to engage in discussions with industry experts on a variety of topics including: the feasibility of real-time motion management on the Radixact® System, tips and tricks to treat localized prostate cancer with the CyberKnife System, tips and tricks for TomoDirect™ breast treatment planning, re-treatment with PreciseRTX™ Re-treatment option, and adaptive radiation therapy using PreciseART™ Adaptive Radiation Therapy software.

MEVION hosting ESTRO 37 symposium on proton therapy selection, implementation, use

MEVION Medical Systems is hosing a symposium at Estro 37 on selection, implementation and use of next generation proton therapy. Below are details:

First Experience with HYPERSCAN Pencil Beam Scanning

Saturday, April 21st 2018, 13:15 - 14:15

ESTRO Satellite Symposium, CCIB Convention Center Level 1, Room 115

Lunch will be provided and pre-registration is not required.


Strategic Healthcare Decisions: Replacing a LINAC with a Compact Proton Therapy System in an Existing Radiation Oncology Department

Maria Jacobs, Ph.D., CEO, MAASTRO Clinic

Geert Bosmans, Ph.D., Head of Proton Physics

Zuid-Oost Nederland Protonen Therapie Centrum, The Netherlands

Expanding an Existing Proton Therapy Program with a Compact Pencil Beam Scanning System

Jeffrey Bradley, MD, FACR, FASTRO Kling Professor of Radiation Oncology, Medical Director

Kling Proton Therapy Center, Washington University School of Medicine, USA

First Clinical Experience with HYPERSCAN Pencil Beam Scanning

Brian Collins, MD, FCCP Medical Director of Radiation Oncology

Georgetown University, Washington D.C. USA


Elekta MR-linac featured in 42 abstracts at ESTRO 37

Elekta has announced that its transformative MR-linac system is featured in 42 abstracts at the European Society for Radiotherapy and Oncology (ESTRO) 37th Annual Conference. Founding members of the Elekta MR-linac Consortium are presenting 36 abstracts and new collaborators from an ever-growing number of world-class cancer centers are presenting six abstracts. Elekta MR-linac is groundbreaking because it overcomes the technical barriers that have hindered the integration of radiation therapy with real-time high-field 1.5 Tesla (T) MR imaging. It is the only system to truly unlock the imaging capabilities of MR/RT, enabling clinicians to see what they treat in real time and offer each patient truly personalized therapy.

“For decades radiation oncologists have been challenged by the inability to see what we treat in real time, and the expansive body of MR-linac data presented at ESTRO 37 makes it clear that the dawn of a wholly new approach to radiation therapy is on the horizon,” said Ananya Choudhury, MA, PhD, MRCP, FRCR, The Christie NHS Foundation Trust, UK. “These data demonstrate that MR-linac has the potential to transform how cancer is treated by allowing more effective tumor targeting, providing better protection for healthy tissue and organs at risk, reducing side effects and enabling real-time adaptation of treatment plans. The ability to see what we treat has the potential to fundamentally change the way we currently treat patients and enable the radiation oncology community to dramatically improve health outcomes.”  

The Elekta MR-linac Consortium is a collaborative industrial-academic partnership that Elekta founded with seven centers and its technology partner, Philips, in 2012 to provide an evidence-based introduction of Elekta MR-linac to the medical community, and to support the advancement of the technology.

Key findings presented at ESTRO 37 include:

  •  1.5T MRI-Linac treatment planning for multiple lymph node oligometastases in the pelvic area (Presentation number OC-0616, oral presentation, Monday, April 23). This study investigated the MR-linac treatment plan quality of multiple lymph node oligometastases in the pelvic area in ten patients. Results show that all treatments were delivered to the target area while protecting organs at risk. This study shows that multiple lymph node oligometastases could potentially be identified and treated on the MR-linac with plan quality and conformity that meet international criteria. Results also suggest that MR-linac may enable the use of smaller treatment target volumes, which could pave the way for further dose escalation and hypofractionation.
  • Investigating online adaptive workflows for prostate patients on the MR-Linac: an in-silico study (Presentation number OC-0615, oral presentation, Monday, April 23). This study investigated three methods for rapidly adjusting treatment plans to account for changes in rectal volume in patients with prostate cancer. Results show that currently available methods can be used for daily re-planning strategies. The optimal method (Segment Weight and Shape Optimization, or SSO) enabled treatment replanning in 239 seconds, which should be feasible for daily plan adjustment in real-world clinical settings.
  • Optimizing acquisition speed and contrast of respiratory correlated 4D-MRI on a 1.5T MRI-Linac (Presentation number PV-0535, poster presentation, Monday, April 23). Internal organs can move during radiation therapy due to breathing, digestion and other normal functions. This study assessed the quality of images using several approaches to account for respiratory motion and also sought to identify the optimum speed for acquiring images to account for abdominal motion in healthy volunteers. Motion of internal organs during radiation therapy due to breathing and other anatomic functions. Results show that four-dimensional MR images were successfully acquired on a 1.5T MR-linac with one of the approaches (self-navigated GA-SoS 4D-MRI). They also demonstrate the feasibility of characterizing abdominal motion even when using only 19% - 38% of the captured image data. The ability to accurately characterize motion with a more limited data set should reduce acquisition time, which is an important factor in making MR-linac compatible with real world clinical workflows.

“The 42 abstracts presented at this conference is continued evidence of the intensity of the work of the Elekta MR-linac Consortium which has resulted in 125 scientific papers on Elekta’s MR-linac, more than any other MR-guided radiation delivery system,” said Elekta CEO, Richard Hausmann. “With this expert community, Elekta has achieved a technical tour-de-force by working with those on the front line of cancer therapy to innovative next-generation technologies that address unmet needs. We recognize the critical role that the consortium members played in making the ability to see what is treated in real-time a reality, and in developing the clinical protocols and processes that will enable MR/RT and transform patient care as we gear up for pending market introduction.”  

Additional information about Elekta MR-linac can be found at .

Elekta MR-linac is a work in progress and not available for sale or distribution.


Back To Top

ESTRO 37: Vendor launches, updates and highlights in Barcelona.  Appl Rad Oncol. 

By News Release| April 20, 2018
Categories:  Section

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd

    Agility CMS